Details

Autor(en) / Beteiligte

• Gilbert, Peter B
• Montefiori, David C
• McDermott, Adrian B
• Fong, Youyi
• Benkeser, David
• Deng, Weiping
• Zhou, Honghong
• Houchens, Christopher R
• Martins, Karen
• Jayashankar, Lakshmi
• Castellino, Flora
• Flach, Britta
• Lin, Bob C
• O'Connell, Sarah
• McDanal, Charlene
• Eaton, Amanda
• Sarzotti-Kelsoe, Marcella
• Lu, Yiwen
• Yu, Chenchen
• Borate, Bhavesh
• van der Laan, Lars W P
• Hejazi, Nima S
• Huynh, Chuong
• Miller, Jacqueline
• El Sahly, Hana M
• Baden, Lindsey R
• Baron, Mira
• De La Cruz, Luis
• Gay, Cynthia
• Kalams, Spyros
• Kelley, Colleen F
• Andrasik, Michele P
• Kublin, James G
• Corey, Lawrence
• Neuzil, Kathleen M
• Carpp, Lindsay N
• Pajon, Rolando
• Follmann, Dean
• Donis, Ruben O
• Koup, Richard A

Titel

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Ist Teil von

• Science (American Association for the Advancement of Science), 2022-01, Vol.375 (6576), p.43-50

Ort / Verlag

United States: The American Association for the Advancement of Science

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time of second vaccination and 4 weeks later, with values reported in standardized World Health Organization international units. All markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Vaccine recipients with postvaccination 50% neutralization titers 10, 100, and 1000 had estimated vaccine efficacies of 78% (95% confidence interval, 54 to 89%), 91% (87 to 94%), and 96% (94 to 98%), respectively. These results help define immune marker correlates of protection and may guide approval decisions for messenger RNA (mRNA) COVID-19 vaccines and other COVID-19 vaccines.